Shanxi Xinbaoyuan Pharmaceutical Co., Ltd.

Main study objectives Healthy subjects were given a single oral dose of the test preparation nifedipine controlled-release tablets (specification: 90 mg) produced by Shanxi Xinbaoyuan Pharmaceutical Co., Ltd. or the reference preparation nifedipine controlled-release tablets (trade name: PROCARDIA XL®; specification: 90 mg) produced by Pfizer Laboratories Div Pfizer Inc. in the fasting or postprandial state to investigate the pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects, respectively, and to evaluate the bioequivalence of the two preparations. Secondary study objectives Investigate the safety of the test preparation and the reference preparation in healthy subjects.

1. To study the pharmacokinetic characteristics of colloidal pectin bismuth granules, bismuth potassium citrate tablets and bismuth potassium citrate granules in healthy subjects after a single oral fasting dose. 2. Using bismuth potassium citrate tablets (gastrodenol) from TORA LABORATORIES.S.L and bismuth potassium citrate granules (Livzon Dele) produced by Livzon Pharmaceutical Factory of Livzon Group as reference preparations and colloidal pectin bismuth granules as test preparations, the pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ of the reference preparations and the test preparations after a single fasting dose were compared, and the safety of the test preparations was evaluated.

This study investigates whether there are differences in the absorption rate and extent between a single oral dose of the test formulation estazolam tablets (Shanxi Shuangyan Pharmaceutical Co., Ltd., specification: 1 mg) and the reference formulation estazolam tablets (trade name: EURODIN®; Teva Takeda Yakuhin Ltd./武田テバ薬品株式会社, specification: 1 mg) after a meal in healthy study participants. It also evaluates the bioequivalence of the test and reference formulations when administered after a meal and observes their safety in healthy study participants.